Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN 8.5% vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% is a crystalline amino acid solution that provides a source of nitrogen and essential/non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for metabolic pathways, including gluconeogenesis and ketogenesis, and supports immune function and enzyme production.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (11.8-17.6 mL/kg/day of 8.5% solution) via central line; rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Variable; amino acids have rapid distribution and metabolic half-lives of minutes to hours; terminal half-life of infused amino acid mixtures is approximately 1–2 hours for most components in patients with normal hepatic function
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Renal elimination of infused amino acids as urea, ammonia, and other nitrogenous waste products; minimal biliary/fecal excretion (<2%)
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution